anaemia in patients with non-haematological malignancies
Anaemia of cancer is present in 40% of patients with nonmyeloid malignancies. It is mild in 30%, moderate in 9% and severe in 1%. Overall incidence of anaemia during chemoor radiotherapy is 54% (mild 39%, moderate 14% and severe 1%). The incidence is highest in patients with lung (71%) or gynaecological cancer (65%) and increases with the number of chemotherapy cycles.
anaemia in patients with haematological malignancies
Anaemia can be present in myelodysplastic syndromes (incidence of 60%-80%), all types of leukaemia (acutechronic; lymphoid or myeloid), in multiple myeloma and lymphoma (71.6% at diagnosis) as well as thalassaemia and sickle cell anaemia. It may also be due to chemotherapeutic treatment for haematological conditions, after autologous stem cell transplantation, or bone marrow failure states.
evaluation of anaemia in cancer patients
grading of anaemia Treatment-related anaemia is graded according to the National Cancer Institute-Common Toxicity Criteria of Adverse Events (CTCAEv3) (Hb grade 0: within normal limits; grade 1: lower normal limit 10.0 g/dl; grade 2: 8.0 to <10.0 g/dl; grade 3: 6.5 to <8.0 g/dl; grade 4: <6.5 g/dl; grade 5: death).
evaluation of anaemia
Patients with anaemia should be evaluated by a thorough history with emphasis on medication use; a blood examination including the reticulocyte count, iron, transferring saturation (TFS) and ferritin levels, C-reactive protein, folate and vitamin B12 status and a peripheral blood smear and if indicated a bone marrow examination; by an assessment of occult blood loss in stool and urine; and by evaluation of the renal function [D] .
Coombs testing should be considered in patients with chronic lymphocytic leukaemia, non-Hodgkin's lymphoma and in patients with a history of autoimmune disease [D] .
Endogenous erythropoietin (EPO) levels may be determined to predict response in patients with myelodysplasia [D] .
All causes of anaemia should be taken into account and, if possible, corrected before the use of erythropoiesis-stimulating agents (ESAs) [B] .
Anaemia has a negative impact on the quality of life (QoL) [I] and is an important factor in cancer-related fatigue [II] .
It also constitutes a negative prognostic factor for overall survival in most types of cancer [I] .
indications for the use of ESAs Treatment recommendations according to label are given in Table 1 and can be followed if there is no suspicion of functional iron deficiency (ferritin >100 ng/ml and TFS saturation <20%).
If the Hb increase is at least 1 g/dl above baseline after 4 weeks of treatment, the dose may remain the same or may be decreased by 25%-50%. If the Hb increase is <1 g/dl above baseline, the dose of selected ESA should be increased (Table 1) . If after an additional 4 weeks of therapy, the Hb has increased by ‡1 g/dl, the dose may remain the same or may be decreased by 25%-50%. In the case of response, treatment with ESAs should be discontinued 4 weeks after the end of chemotherapy. If the Hb increase is <1 g/dl above baseline after 8-9 weeks of therapy, response to ESA therapy is unlikely and treatment should be discontinued. If the Hb rises by >2 g/dl per 4 weeks or if the Hb exceeds 12 g/dl, the dose should be reduced by 25%-50%. If the Hb exceeds 13 g/dl, therapy should be discontinued until Hb falls below 12 g/dl and then reinstituted at a dose 25% below the previous dose.
Treatment with ESAs in patients with chemotherapy-induced anaemia increases Hb levels with an overall weighted mean difference of 1.63 g/dl [95% confidence interval (CI) 1.46- bone marrow transplantation. Shortly after autologous transplantation there is a reduced response to EPO, although endogenous EPO is produced by the kidney in appropriately increased amounts. Later responsiveness of the transplanted marrow to EPO recovers and transfusion requirements decrease.
After an allogeneic transplantation, there is a faster response to EPO of the bone marrow. Thereafter, inflammatory cytokines, characteristic of graft-versus-host disease and immunosuppressive therapy cause not only a reduction in endogenous EPO production but also a diminished response to EPO. ESA therapy has been shown to be effective after allogeneic transplantation, although at somewhat higher doses of 75-200 IU/kg [B]. 
recommendations in relation to iron
Baseline and periodic monitoring of iron, C-reactive protein, TFS and ferritin levels are necessary [D] . In anaemic patients with iron deficiency, intravenous iron supplementation leads to higher Hb increment in comparison with oral or no iron substitution [II, A].
Iron supplementation also appears to reduce the numbers of patients receiving RBCTs [I] .
cancer therapy outcome
The influence of ESAs on tumour response and overall survival in anaemic cancer patients remains unclear. Several randomized trials have demonstrated decreased survival times and poorer locoregional control or progression-free survival but the design of these studies was aimed at Hb levels of >12 g/dl and included patients with a baseline Hb level of >11 g/dl [II] .
In one meta-analysis, there was no effect on disease-free survival or disease progression in patients treated with chemotherapy in combination with darbepoietin [I] .
Other recent meta-analyses showed that ESAs increased mortality [combined hazard ratio (cHR) 1.17, 95% CI 1.06-1.30; RR 1.15; 95% CI 1.03-1.29] and worsened overall survival (cHR 1.06, 95% CI 1.00-1.12) when given to cancer patients.
In all three meta-analyses, patients treated with chemotherapy had no increased mortality (HR 0.97, 95% CI 0.85-1.1; cHR 1.10, 95% CI 0.98-1.24; 1.04, 95% CI 0.86-1.26).
safety and tolerability
ESAs should not be used in patients with a known hypersensitivity to ESAs or any of the excipients and in patients with poorly controlled hypertension [B] . Their effect on patients with impaired liver function is unknown and they should be used with caution in patients with liver disease [D] .
The relative risk of thromboembolic events is increased by 67% in patients treated with ESAs compared with placebo (RR 1.67; 95% CI 1.35-2.06) [I] . The use of ESAs should be carefully reconsidered in patients with a high risk of thromboembolic events such as a previous history of thrombosis, surgery, prolonged immobilization or limited activity and in patients with multiple myeloma and treated with thalidomide or lenalidomide in combination with doxorubicin and corticosteroids [D] . There are no data on the preventive use of anticoagulants or aspirin.
Pure red cell aplasia (PRCA) caused by neutralizing antierythropoietin antibodies has been observed in association with ESAs in patients with chronic renal failure [V], although no PRCA has been reported in cancer patients. This was likely due to manufacturing issues [II, B] .
Other side-effects of ESAs are rare allergic reactions including dyspnoea, skin rash and urticaria; arthralgia; peripheral oedema; and mild and transient injection site pain [I] .
pharmaco-economic considerations
Use of ESAs profoundly increases health care costs [I] and the cost per quality-adjusted life-year (QALY) is estimated to be €208 000 since there seems to be no survival benefit [II] . 
